Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01149837 · ClinicalTrials.gov registry record

Evaluation of InnoLIA HTLV I/II Score

A clinical trial of Human T-Lymphotrophic Virus Type I and/or Type II, sponsored by Creative Testing Solutions.

Completed
Registry status
3,305
Enrollment target
1
Study location

NCT01149837 is a study of Human T-Lymphotrophic Virus Type I and/or Type II that has completed, run by Creative Testing Solutions. The registered enrollment target is 3,305 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01149837, a study of Human T-Lymphotrophic Virus Type I and/or Type II, has completed, sponsored by Creative Testing Solutions.

COMPLETED
Registry status
3,305 participants
Enrollment target
1
Study location

Study Summary

The InnoLIA HTLV I/II Score is an in vitro diagnostic test for confirmation of antibodies to human T-cell lymphotropic virus (HTLV) type I and type II in human blood samples. It is intended as a supplemental test for blood donor samples that are reactive in routine anti-HTLV screening tests. This study will determine if the test is useful for donor counseling purposes.

Interventions

  • DEVICE InnoLIA HTLV I/II Score line immunoassay

Study Locations (1)

Arizona

  • Creative Testing Solutions - Tempe

Trial Details

FieldValue
Enrollment Target 3,305 participants
Start Date 2013-07
Est. Completion 2019-01-25

Sponsor

Creative Testing Solutions

1 total trials

What the Registry Record Tells You About NCT01149837

The ClinicalTrials.gov registry entry for NCT01149837 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,305 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Creative Testing Solutions, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Human T-Lymphotrophic Virus Type I and/or Type II appearing as the primary indexed condition, and to 1 intervention - of which InnoLIA HTLV I/II Score line immunoassay is the first listed.

NCT01149837 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT01149837 about?

NCT01149837 is a clinical study titled "Evaluation of InnoLIA HTLV I/II Score". The InnoLIA HTLV I/II Score is an in vitro diagnostic test for confirmation of antibodies to human T-cell lymphotropic virus (HTLV) type I and type II in human blood samples. It is intended as a supplemental test for blood donor samples that are reactive in routine anti-HTLV screening tests. This st...

What is the current status of trial NCT01149837?

This trial is currently completed. The enrollment target is 3,305 participants. The study started on 2013-07. Estimated completion is 2019-01-25.

What conditions does trial NCT01149837 study?

This clinical trial studies the following conditions: Human T-Lymphotrophic Virus Type I and/or Type II.

What interventions are being tested in trial NCT01149837?

The interventions under investigation include: InnoLIA HTLV I/II Score line immunoassay (DEVICE).

Who is sponsoring clinical trial NCT01149837?

This trial is sponsored by Creative Testing Solutions, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01149837 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.